# Neurelis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurelis

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.neurelis.com
- Total disclosed funding: $142M
- Latest round: Series D (Feb 26, 2021)
- Investors on record: 5

## About

Based in the US, Neurelis, Inc. operates as a biopharmaceutical company dedicated to developing innovative treatments for neurological conditions, particularly focusing on epilepsy management through their advanced therapeutic solutions.Neurelis, Inc. specializes in developing treatments for neurological disorders, with its headquarters located in San Diego, US. Founded in 2007 by Craig Chambliss, Neurelis has undergone operational changes, focusing on expanding its product offerings. The company has completed 9 deals, with the most recent deal occurring on June 4, 2013, when Biotie Therapies Corp. agreed to acquire Neurelis, with financial terms undisclosed. Neurelis has raised a total of USD 114.76 mn through its last funding round, SERIES D, with investors including Cormorant Asset Management and Decheng Capital. The current company valuation stands at USD 534.55 mn.Neurelis, Inc. specializes in developing innovative solutions for individuals living with neurological conditions, focusing primarily on epilepsy management. Their core product, VALTOCO™, is a nasal spray formulation designed for the rapid treatment of seizure clusters in patients with epilepsy. This non-invasive drug delivery system is developed using Neurelis's proprietary technologies, including Intravail®, ProTek®, and Hydrogel™, enhancing the delivery and stabilization of therapeutic molecules. The company aims to address unmet medical needs by providing effective treatment options for patients and their caregivers, ensuring they can manage their condition while maintaining a quality of life. Neurelis's solutions serve a diverse client base, including healthcare providers, caregivers, and patients across various geographical markets, including the United States and select international markets.Neurelis generates revenue primarily through the sale of its flagship product, VALTOCO™, marketed to healthcare providers and distributed through various channels, including pharmacies and hospitals. The revenue model is structured around direct-to-consumer sales and partnerships with healthcare institutions, involving prescription fulfillment for patients experiencing seizure clusters. Neurelis also collaborates with other pharmaceutical companies to enhance its product pipeline and expand its market reach, ensuring accessibility and affordability for those living with neurological conditions.Neurelis plans to utilize its recent funding to support the development of new products and expand into new markets. The company is designing additional therapies aimed at enhancing epilepsy management, although specific release dates are not disclosed. Geographically, Neurelis is targeting expansion into select international markets by 2025. The funding from the SERIES D round, amounting to USD 114.76 mn, will support these strategic initiatives, reinforcing the company’s commitment to improving treatment access for individuals with neurological disorders.

## Funding rounds

- Series D, Feb 26, 2021, $115M — HBM Partners, Decheng Capital, Cormorant Asset Management, LYZZ Capital, Philos & Partners
- Series C, Oct 15, 2020, $27M — HBM Partners
- Series B, Jan 5, 2017 — HBM Partners, LYZZ Capital

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C, Series D
- LYZZ Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B, Series D
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- Philos & Partners — Series D